BackgroundCanakinumab is a IgG1 anti-interleukin-1β monoclonal antibody indicated in the treatment of Muckle–Wells syndrome (MWS). It is an autosomal dominant congenital disease that is considered a rare disease. Hives, joint pains, conjunctivitis, deafness, amyloidosis and fever are its symptoms. For years, the only available treatments were non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticoids.PurposeThe objective of this study was to determine the effectiveness of canakinumab in the treatment of MWS in patients who have failed treatment with NSAIDs and systemic corticoids.Material and methodsAn observational retrospective study was carried out in a tertiary care hospital from February 2011 to October 2016. Patients who were treated with canakinumab during this period were selected. The data was obtained from the electronic software used in the hospital (Landtools). Indication, posology, duration of treatment, previous therapy, adverse effects and C reactive protein (CRP) levels were collected from patients’ digital history. Suspension of treatment with canakinumab was also registered. Remission was defined as clinical improvement plus normal CRP (<6 mg/L). Available treatments were NSAIDs and systemic corticoids.Results6 patients were selected; median age 52 years (36–66 years). The indication for treatment with canakinumab was MWS. Patients received canakinumab 150 mg subcutaneously every 8 weeks (n=5) or 12 weeks (n=1) for a median of 47 months (range 24–70). All patients had received corticoids and NSAIDs with no suitable response. Other previous therapies were antihistamines, methotrexate, colchicine, infliximab, etanercept and hydroxychloroquine. Canakinumab was well tolerated; 1 patient experienced an injection site reaction.Treatment with canakinumab caused a significant reduction in clinical disease activity and CRP levels (average before treatment of 40.7 mg/L (3.7–81.2 mg/L) versus average after treatment of 19.27 mg/L (0.45–86.03 mg/L)). 50% (n=3) of canakinumab treated patients achieved remission. All patients are currently receiving treatment.ConclusionCanakinumab is an effective therapeutic alternative for the treatment of MKS if poor effects have been achieved on other therapies. The observed evolution was favourable, being safe and well tolerated.References and/or acknowledgementsOrphanet guide.No conflict of interest
flushes (7.7%); four thrombocytopaenia, three cases grade 1 (11.5%) and one case grade 3 (3.8%); and two alopecia grade 1 (7.7%); Of all of them, there were a total of seven temporary treatment suspensions (26.9%) and four dose reductions (15.3%). Conclusion With the results of our study, we wanted to show the safety profile of these new drugs, although the reflected data do not allow comparisons with clinical trials due to the small sample size. Future studies will allow to make these comparisons, because the advantages that these drugs bring in effectiveness will lead to considerable increases in their use.
BackgroundNeurology is one of the medical specialities in which botulinum toxin (BT) provides greater therapeutic benefits due to its ability to produce muscle paralysis, which can be used to treat certain neurological diseases involving muscle hyperactivity.PurposeTo analyse the prescription profile of BT type A in neurological diseases and prescription suitability based on the data sheet, comparing the frequency of administration between the different approved indications.Material and methodsA retrospective observational study of the prescription profile and frequency of administration of BT was conducted in the neurology department of a third level hospital. All patients with at least two administrations of BT were included during the period January and September 2016. Prescription suitability was determined based on the approved indications in the drug data sheet of the three BT type A available in the hospital: Botox, Dysport and Xeomin. Data were collected from clinical histories and outpatient dispensing software Farmatools. ANOVA test (SPSS) was used to compare differences between the frequency of administration of each approved indication.Results83 patients were included. 79% received BT for one approved indication. Hemifacial spasm was the most common authorised diagnosis (31%), followed by blepharospasm (13%), different types of spasticity (13%), migraine (12%) and cervical dystonia (10%). The average frequency of administration in patients with hemifacial spasm, cervical dystonia, spasticity (stroke or cerebral palsy origin) and blepharospasm were 6.1 months (95% CI 5.1–7.0); 5.0 months (95% CI 4.1–5.9); 4.6 months (95% CI 3.5–5.7); and 4.6 months (95% CI 3.9–5.7), respectively (p=0.332). The frequency of injection in patients with migraine was 3.8 months (95% CI 2.9–3.9), existing differences that were statistically significant with the hemifacial spasm indication (p=0.009). In 17 patients, BT was used in off-label indications: dystonia (generalised, cranial and oropharyngeal) (n=9); writer’s cramp (n=5); bruxism (n=2); and facial pain (n=1).ConclusionBT was used in a high percentage for approved indications (79%), hemifacial spasm being the most prevalent. Significant differences in the frequency of administration between migraine and hemifacial spasm were observed. The more common off-label indications were dystonia and writer’s cramp.References and/or acknowledgementsBotox, XeominandDysport data sheet (available at ).No conflict of interest
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.